HNSA-5487
HNSA-5487 is Hansa Biopharma’s next-generation IgG-cleaving enzyme with the potential to prolong the IgG-low window.
In 2024, Hansa completed the first-in-human trial (NICE-01) of HNSA-5487 including 12-month follow up analysis, reporting positive results on safety and tolerability and an attractive immunogenicity profile with a clear redosing potential.
Hansa is focusing clinical development of HNSA-5487 in chronic neuro-autoimmune conditions where IgG plays a role in disease pathology and acute phases.
HNSA-5487 is the lead molecule in the Novel IgG Cleaving Enzyme for Repeat Dosing (NiceR) Program, Hansa's next generation IgG-cleaving enzyme program. It is in preclinical development and is designed to enable expansion into a large spectrum of potential indications, including relapsing autoimmune diseases and gene therapy, as well as oncology indications.
